AGP Executive Report
Last update: an hour agoAI in Prescribing: Utah’s AI prescribing pilot (Doctronic) is showing early traction—AI recommended renewals in 72% of cases, and physicians agreed 91% of the time, with escalations usually triggered by missing labs or complications. Duchenne Drug Push: Dyne submitted a biologics license application to the FDA for z-rostudirsen (exon 51 skipping), aiming for accelerated approval; Priority Review is being sought with a potential 2027 U.S. launch. FDA Animal-Drug Funding: The FDA is accepting FY2027 grant applications for its MUMS program to support development of animal drugs for uncommon diseases. Hospital Care Continuity: Massachusetts DOC rolled out tablets for clinicians to access real-time inmate medical and mental health records, responding to recommendations after suicide deaths. Cardio Tech Update: PROACTIVE-HF 2-year data says the Cordella pulmonary artery sensor improved heart-failure status across ejection-fraction groups. Oncology Diagnostics: FDA approved FoundationOne CDx for tepotinib in MET exon 14 skipping NSCLC. Weight-Loss Generics: Brazil’s Anvisa approved EMS’s semaglutide pen (Ozivy) after Ozempic patent expiry, pending pricing and SUS inclusion steps.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.
Perspectify News
